Synairgen (LON:SNG) Trading Down 11.4% – Should You Sell?

Synairgen plc (LON:SNG)’s share price was down 11.4% on Tuesday . The company traded as low as GBX 2.01 ($0.03) and last traded at GBX 2.06 ($0.03). Approximately 371,522 shares traded hands during trading, a decline of 80% from the average daily volume of 1,901,132 shares. The stock had previously closed at GBX 2.33 ($0.03).

Synairgen Stock Down 8.2 %

The stock’s 50-day moving average price is GBX 2.71 and its two-hundred day moving average price is GBX 3.62. The company has a current ratio of 6.77, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of £4.07 million, a P/E ratio of -67.33 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).